TFFP: TFF Pharmaceuticals, Inc. Stock

by  •  • Comments Off on TFFP: TFF Pharmaceuticals, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 7.78
Enterprise Value ($M) 2.31
Book Value ($M) 9.57
Book Value / Share 3.80
Price / Book 0.81
NCAV ($M) 5.13
NCAV / Share 2.04
Price / NCAV 1.52

Profitability (mra)
Return on Invested Capital (ROIC) -2.19
Return on Assets (ROA) -1.17
Return on Equity (ROE) -1.28

Liquidity (mrq)
Quick Ratio 3.13
Current Ratio 3.13

Balance Sheet (mrq) ($M)
Current Assets 7.59
Assets 12.03
Liabilities 2.46
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.73
Operating Income -21.89
Net Income -21.24

Cash Flow Statement (mra) ($M)
Cash From Operations -16.04
Cash from Investing -0.09
Cash from Financing 5.01

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-14 13G/A Lytton Laurence W 0.10 -99.62

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-03-28 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT UNDER SECTION 13
2023-11-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT
2023-08-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO S
2023-05-11 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-04-26 4,924 34,013 14.48
2024-04-25 14,040 1,124 1,249.11
2024-04-24 748 626 119.49
2024-04-23 22,548 12,439 181.27
2024-04-22 14,005 6,999 200.10

(click for more detail)

Similar Companies
TCRT – Alaunos Therapeutics, Inc. TELO – Telomir Pharmaceuticals, Inc.
TENX – Tenax Therapeutics, Inc. TGTX – TG Therapeutics, Inc.
THAR – Tharimmune, Inc.


Financial data and stock pages provided by
Fintel.io